private:crescendobiologics
|
790363
|
Nov 18th, 2019 12:00AM
|
Crescendo Biologics Limited
|
1.7K
|
55.00
|
Open
|
Biotechnology
|
Nov 18th, 2019 04:05PM
|
Nov 18th, 2019 04:05PM
|
Crescendo Biologics is a biopharmaceutical company developing potent, truly differentiated Humabody®
therapeutics in oncology with a focus on innovative targeted T-cell approaches.
Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel bispecific PSMA-targeted
T-cell engager for the selective activation of tumour-specific T-cells exclusively within the tumour
microenvironment, thereby avoiding systemic toxicity. This highly modular format can be re-configured to
create a pipeline of multiple therapeutic candidates each treating a different cancer indication, by targeting
any of a range of alternative tumour-specific markers.
The Company’s ability to develop multi-functional Humabody® therapeutics is based on its unique, patent
protected, transgenic mouse platform generating 100% human VH domain building blocks (Humabody®
VH). These robust molecules can be configured to optimally engage therapeutic targets delivering novel
biology and superior bio-distribution. This results in larger therapeutic windows compared to conventional
IgG approaches.
Crescendo Biologics is pursuing novel Humabody®-based product opportunities, through in-house
development and strategic partnerships, including multi-functional immuno-oncology modulators and
Humabody® drug conjugates (HDCs), the next generation of ADCs. Humabody®-based formats can also be
applied across a range of non-cancer indications.
Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova
Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital, Astellas and EMBL ventures
|
Open
|
|
Open
|
Babraham Research Campus
|
Cambridge
|
|
GB
|
|
|
Crescendo Biologics
|
Health Care
|
Health Care Equipment & Services
|
private:crescendobiologics
|
790363
|
Nov 17th, 2019 12:00AM
|
Crescendo Biologics Limited
|
1.7K
|
55.00
|
Open
|
Biotechnology
|
Nov 17th, 2019 04:30PM
|
Nov 17th, 2019 04:30PM
|
Crescendo Biologics is a biopharmaceutical company developing potent, truly differentiated Humabody®
therapeutics in oncology with a focus on innovative targeted T-cell approaches.
Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel bispecific PSMA-targeted
T-cell engager for the selective activation of tumour-specific T-cells exclusively within the tumour
microenvironment, thereby avoiding systemic toxicity. This highly modular format can be re-configured to
create a pipeline of multiple therapeutic candidates each treating a different cancer indication, by targeting
any of a range of alternative tumour-specific markers.
The Company’s ability to develop multi-functional Humabody® therapeutics is based on its unique, patent
protected, transgenic mouse platform generating 100% human VH domain building blocks (Humabody®
VH). These robust molecules can be configured to optimally engage therapeutic targets delivering novel
biology and superior bio-distribution. This results in larger therapeutic windows compared to conventional
IgG approaches.
Crescendo Biologics is pursuing novel Humabody®-based product opportunities, through in-house
development and strategic partnerships, including multi-functional immuno-oncology modulators and
Humabody® drug conjugates (HDCs), the next generation of ADCs. Humabody®-based formats can also be
applied across a range of non-cancer indications.
Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova
Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital, Astellas and EMBL ventures
|
Open
|
|
Open
|
Babraham Research Campus
|
Cambridge
|
|
GB
|
|
|
Crescendo Biologics
|
Health Care
|
Health Care Equipment & Services
|
private:crescendobiologics
|
790363
|
Nov 16th, 2019 12:00AM
|
Crescendo Biologics Limited
|
1.7K
|
54.00
|
Open
|
Biotechnology
|
Nov 16th, 2019 04:24PM
|
Nov 16th, 2019 04:24PM
|
Crescendo Biologics is a biopharmaceutical company developing potent, truly differentiated Humabody®
therapeutics in oncology with a focus on innovative targeted T-cell approaches.
Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel bispecific PSMA-targeted
T-cell engager for the selective activation of tumour-specific T-cells exclusively within the tumour
microenvironment, thereby avoiding systemic toxicity. This highly modular format can be re-configured to
create a pipeline of multiple therapeutic candidates each treating a different cancer indication, by targeting
any of a range of alternative tumour-specific markers.
The Company’s ability to develop multi-functional Humabody® therapeutics is based on its unique, patent
protected, transgenic mouse platform generating 100% human VH domain building blocks (Humabody®
VH). These robust molecules can be configured to optimally engage therapeutic targets delivering novel
biology and superior bio-distribution. This results in larger therapeutic windows compared to conventional
IgG approaches.
Crescendo Biologics is pursuing novel Humabody®-based product opportunities, through in-house
development and strategic partnerships, including multi-functional immuno-oncology modulators and
Humabody® drug conjugates (HDCs), the next generation of ADCs. Humabody®-based formats can also be
applied across a range of non-cancer indications.
Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova
Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital, Astellas and EMBL ventures
|
Open
|
|
Open
|
Babraham Research Campus
|
Cambridge
|
|
GB
|
|
|
Crescendo Biologics
|
Health Care
|
Health Care Equipment & Services
|
private:crescendobiologics
|
790363
|
Nov 15th, 2019 12:00AM
|
Crescendo Biologics Limited
|
1.7K
|
54.00
|
Open
|
Biotechnology
|
Nov 15th, 2019 01:02PM
|
Nov 15th, 2019 01:02PM
|
Crescendo Biologics is a biopharmaceutical company developing potent, truly differentiated Humabody®
therapeutics in oncology with a focus on innovative targeted T-cell approaches.
Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel bispecific PSMA-targeted
T-cell engager for the selective activation of tumour-specific T-cells exclusively within the tumour
microenvironment, thereby avoiding systemic toxicity. This highly modular format can be re-configured to
create a pipeline of multiple therapeutic candidates each treating a different cancer indication, by targeting
any of a range of alternative tumour-specific markers.
The Company’s ability to develop multi-functional Humabody® therapeutics is based on its unique, patent
protected, transgenic mouse platform generating 100% human VH domain building blocks (Humabody®
VH). These robust molecules can be configured to optimally engage therapeutic targets delivering novel
biology and superior bio-distribution. This results in larger therapeutic windows compared to conventional
IgG approaches.
Crescendo Biologics is pursuing novel Humabody®-based product opportunities, through in-house
development and strategic partnerships, including multi-functional immuno-oncology modulators and
Humabody® drug conjugates (HDCs), the next generation of ADCs. Humabody®-based formats can also be
applied across a range of non-cancer indications.
Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova
Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital, Astellas and EMBL ventures
|
Open
|
|
Open
|
Babraham Research Campus
|
Cambridge
|
|
GB
|
|
|
Crescendo Biologics
|
Health Care
|
Health Care Equipment & Services
|
private:crescendobiologics
|
790363
|
Nov 13th, 2019 12:00AM
|
Crescendo Biologics Limited
|
1.7K
|
54.00
|
Open
|
Biotechnology
|
Nov 13th, 2019 01:26PM
|
Nov 13th, 2019 01:26PM
|
Crescendo Biologics is a biopharmaceutical company developing potent, truly differentiated Humabody®
therapeutics in oncology with a focus on innovative targeted T-cell approaches.
Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel bispecific PSMA-targeted
T-cell engager for the selective activation of tumour-specific T-cells exclusively within the tumour
microenvironment, thereby avoiding systemic toxicity. This highly modular format can be re-configured to
create a pipeline of multiple therapeutic candidates each treating a different cancer indication, by targeting
any of a range of alternative tumour-specific markers.
The Company’s ability to develop multi-functional Humabody® therapeutics is based on its unique, patent
protected, transgenic mouse platform generating 100% human VH domain building blocks (Humabody®
VH). These robust molecules can be configured to optimally engage therapeutic targets delivering novel
biology and superior bio-distribution. This results in larger therapeutic windows compared to conventional
IgG approaches.
Crescendo Biologics is pursuing novel Humabody®-based product opportunities, through in-house
development and strategic partnerships, including multi-functional immuno-oncology modulators and
Humabody® drug conjugates (HDCs), the next generation of ADCs. Humabody®-based formats can also be
applied across a range of non-cancer indications.
Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova
Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital, Astellas and EMBL ventures
|
Open
|
|
Open
|
Babraham Research Campus
|
Cambridge
|
|
GB
|
|
|
Crescendo Biologics
|
Health Care
|
Health Care Equipment & Services
|
private:crescendobiologics
|
790363
|
Nov 12th, 2019 12:00AM
|
Crescendo Biologics Limited
|
1.7K
|
54.00
|
Open
|
Biotechnology
|
Nov 12th, 2019 03:07PM
|
Nov 12th, 2019 03:07PM
|
Crescendo Biologics is a biopharmaceutical company developing potent, truly differentiated Humabody®
therapeutics in oncology with a focus on innovative targeted T-cell approaches.
Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel bispecific PSMA-targeted
T-cell engager for the selective activation of tumour-specific T-cells exclusively within the tumour
microenvironment, thereby avoiding systemic toxicity. This highly modular format can be re-configured to
create a pipeline of multiple therapeutic candidates each treating a different cancer indication, by targeting
any of a range of alternative tumour-specific markers.
The Company’s ability to develop multi-functional Humabody® therapeutics is based on its unique, patent
protected, transgenic mouse platform generating 100% human VH domain building blocks (Humabody®
VH). These robust molecules can be configured to optimally engage therapeutic targets delivering novel
biology and superior bio-distribution. This results in larger therapeutic windows compared to conventional
IgG approaches.
Crescendo Biologics is pursuing novel Humabody®-based product opportunities, through in-house
development and strategic partnerships, including multi-functional immuno-oncology modulators and
Humabody® drug conjugates (HDCs), the next generation of ADCs. Humabody®-based formats can also be
applied across a range of non-cancer indications.
Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova
Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital, Astellas and EMBL ventures
|
Open
|
|
Open
|
Babraham Research Campus
|
Cambridge
|
|
GB
|
|
|
Crescendo Biologics
|
Health Care
|
Health Care Equipment & Services
|
private:crescendobiologics
|
790363
|
Nov 11th, 2019 12:00AM
|
Crescendo Biologics Limited
|
1.7K
|
55.00
|
Open
|
Biotechnology
|
Nov 11th, 2019 03:05PM
|
Nov 11th, 2019 03:05PM
|
Crescendo Biologics is a biopharmaceutical company developing potent, truly differentiated Humabody®
therapeutics in oncology with a focus on innovative targeted T-cell approaches.
Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel bispecific PSMA-targeted
T-cell engager for the selective activation of tumour-specific T-cells exclusively within the tumour
microenvironment, thereby avoiding systemic toxicity. This highly modular format can be re-configured to
create a pipeline of multiple therapeutic candidates each treating a different cancer indication, by targeting
any of a range of alternative tumour-specific markers.
The Company’s ability to develop multi-functional Humabody® therapeutics is based on its unique, patent
protected, transgenic mouse platform generating 100% human VH domain building blocks (Humabody®
VH). These robust molecules can be configured to optimally engage therapeutic targets delivering novel
biology and superior bio-distribution. This results in larger therapeutic windows compared to conventional
IgG approaches.
Crescendo Biologics is pursuing novel Humabody®-based product opportunities, through in-house
development and strategic partnerships, including multi-functional immuno-oncology modulators and
Humabody® drug conjugates (HDCs), the next generation of ADCs. Humabody®-based formats can also be
applied across a range of non-cancer indications.
Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova
Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital, Astellas and EMBL ventures
|
Open
|
|
Open
|
Babraham Research Campus
|
Cambridge
|
|
GB
|
|
|
Crescendo Biologics
|
Health Care
|
Health Care Equipment & Services
|
private:crescendobiologics
|
790363
|
Nov 10th, 2019 12:00AM
|
Crescendo Biologics Limited
|
1.7K
|
55.00
|
Open
|
Biotechnology
|
Nov 10th, 2019 06:12PM
|
Nov 10th, 2019 06:12PM
|
Crescendo Biologics is a biopharmaceutical company developing potent, truly differentiated Humabody®
therapeutics in oncology with a focus on innovative targeted T-cell approaches.
Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel bispecific PSMA-targeted
T-cell engager for the selective activation of tumour-specific T-cells exclusively within the tumour
microenvironment, thereby avoiding systemic toxicity. This highly modular format can be re-configured to
create a pipeline of multiple therapeutic candidates each treating a different cancer indication, by targeting
any of a range of alternative tumour-specific markers.
The Company’s ability to develop multi-functional Humabody® therapeutics is based on its unique, patent
protected, transgenic mouse platform generating 100% human VH domain building blocks (Humabody®
VH). These robust molecules can be configured to optimally engage therapeutic targets delivering novel
biology and superior bio-distribution. This results in larger therapeutic windows compared to conventional
IgG approaches.
Crescendo Biologics is pursuing novel Humabody®-based product opportunities, through in-house
development and strategic partnerships, including multi-functional immuno-oncology modulators and
Humabody® drug conjugates (HDCs), the next generation of ADCs. Humabody®-based formats can also be
applied across a range of non-cancer indications.
Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova
Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital, Astellas and EMBL ventures
|
Open
|
|
Open
|
Babraham Research Campus
|
Cambridge
|
|
GB
|
|
|
Crescendo Biologics
|
Health Care
|
Health Care Equipment & Services
|
private:crescendobiologics
|
790363
|
Nov 9th, 2019 12:00AM
|
Crescendo Biologics Limited
|
1.7K
|
56.00
|
Open
|
Biotechnology
|
Nov 9th, 2019 05:40PM
|
Nov 9th, 2019 05:40PM
|
Crescendo Biologics is a biopharmaceutical company developing potent, truly differentiated Humabody®
therapeutics in oncology with a focus on innovative targeted T-cell approaches.
Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel bispecific PSMA-targeted
T-cell engager for the selective activation of tumour-specific T-cells exclusively within the tumour
microenvironment, thereby avoiding systemic toxicity. This highly modular format can be re-configured to
create a pipeline of multiple therapeutic candidates each treating a different cancer indication, by targeting
any of a range of alternative tumour-specific markers.
The Company’s ability to develop multi-functional Humabody® therapeutics is based on its unique, patent
protected, transgenic mouse platform generating 100% human VH domain building blocks (Humabody®
VH). These robust molecules can be configured to optimally engage therapeutic targets delivering novel
biology and superior bio-distribution. This results in larger therapeutic windows compared to conventional
IgG approaches.
Crescendo Biologics is pursuing novel Humabody®-based product opportunities, through in-house
development and strategic partnerships, including multi-functional immuno-oncology modulators and
Humabody® drug conjugates (HDCs), the next generation of ADCs. Humabody®-based formats can also be
applied across a range of non-cancer indications.
Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova
Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital, Astellas and EMBL ventures
|
Open
|
|
Open
|
Babraham Research Campus
|
Cambridge
|
|
GB
|
|
|
Crescendo Biologics
|
Health Care
|
Health Care Equipment & Services
|
private:crescendobiologics
|
790363
|
Nov 8th, 2019 12:00AM
|
Crescendo Biologics Limited
|
1.7K
|
56.00
|
Open
|
Biotechnology
|
Nov 8th, 2019 02:50PM
|
Nov 8th, 2019 02:50PM
|
Crescendo Biologics is a biopharmaceutical company developing potent, truly differentiated Humabody®
therapeutics in oncology with a focus on innovative targeted T-cell approaches.
Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel bispecific PSMA-targeted
T-cell engager for the selective activation of tumour-specific T-cells exclusively within the tumour
microenvironment, thereby avoiding systemic toxicity. This highly modular format can be re-configured to
create a pipeline of multiple therapeutic candidates each treating a different cancer indication, by targeting
any of a range of alternative tumour-specific markers.
The Company’s ability to develop multi-functional Humabody® therapeutics is based on its unique, patent
protected, transgenic mouse platform generating 100% human VH domain building blocks (Humabody®
VH). These robust molecules can be configured to optimally engage therapeutic targets delivering novel
biology and superior bio-distribution. This results in larger therapeutic windows compared to conventional
IgG approaches.
Crescendo Biologics is pursuing novel Humabody®-based product opportunities, through in-house
development and strategic partnerships, including multi-functional immuno-oncology modulators and
Humabody® drug conjugates (HDCs), the next generation of ADCs. Humabody®-based formats can also be
applied across a range of non-cancer indications.
Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova
Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital, Astellas and EMBL ventures
|
Open
|
|
Open
|
Babraham Research Campus
|
Cambridge
|
|
GB
|
|
|
Crescendo Biologics
|
Health Care
|
Health Care Equipment & Services
|